Skip to main content Skip to search Skip to main navigation

ICH: Assembly Meeting 2025

The International Council for Harmonisation (ICH) held its Assembly meeting on 13–14 May 2025 in Madrid, Spain, alongside 11 Working Groups and prior meetings of the Management and MedDRA Steering Committees.

Membership Updates
ICH welcomed three new Observers: DINAVISA (Paraguay), MOH (Kuwait), and SRS (El Salvador), bringing the total to 23 Members and 41 Observers. Mr. Daisuke Koga (MHLW/PMDA, Japan) was elected as the new Vice-Chair of the ICH Management Committee.

New Harmonisation Topics
Four new topics were adopted for future guideline development:

  • Use of Real-World Evidence for regulatory decisions
  • Utility of Comparative Efficacy Studies in biosimilar development
  • Natural History Studies and Registry Data in rare disease drug development
  • Comparability of ATMPs following manufacturing changes (Annex to ICH Q5E)

Guideline Progress and Milestones
The Assembly acknowledged progress on several guidelines:

  • Finalised (Step 4):
    • ICH E6(R3): Revised “Good Clinical Practice” guideline adopted in January 2025
  • New Drafts Endorsed (Step 2):
    • ICH M4Q(R2): Updated Common Technical Document (CTD) for pharmaceutical registration.
    • ICH E21: Inclusion of pregnant and breastfeeding individuals in clinical trials.
    • ICH Q1: Stability testing of drug substances and products.
    • ICH M13B: Biowaivers for additional strengths of immediate-release solid oral dosage forms in bioequivalence studies
    • ICH M11: Updated Technical Specification for the electronic protocol standard (CESHARP).
    • ICH M7 Addendum: Framework for assessment and control of DNA-reactive impurities, including nitrosamines.

MedDRA Updates
New MedDRA Steering Committee appointments: NMPA (China), SFDA (Saudi Arabia), and IFPMA (Standing Observer). MedDRA is now used by over 9,000 organizations in 141 countries and available in 24 languages, including Icelandic. The MedDRA LMS, launched in early 2025, offers structured online training.

Next Meeting
The next ICH Assembly will take place on 18–19 November 2025 in Singapore.


Source:

ICH: Press Release


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
 Data Integrity and Data Governance

Data Integrity and Data Governance

Data integrity is a key element in the pharmaceutical quality assurance system which has gained importance in recent years, especially from the viewpoint of the authorities. In GxP-regulated companies, managers are responsible for identifying and minimising risks to data integrity (“data governance”).

Read more
EMA Clarifies “Novel or Complex Manufacturing Process” Definition

EMA Clarifies “Novel or Complex Manufacturing Process” Definition

In its Quality of Medicines Q&A – Part 1, the EMA has clarified how “novel or complex manufacturing processes” should be interpreted for variation categories Q.II.b.1 (new/replacement finished product manufacturing site) and Q.II.b.4 (change in batch size).
Read more
EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

The Environment Committee of the European Parliament has issued its opinion on the proposed EU Regulation to strengthen the availability of critical medicines. Key recommendations include fast-track permitting, simplified environmental assessments, and support for strategic manufacturing projects to boost EU production capacity.
Read more
Previous
Next